T1	Person 0 3	Age
T2	Value 4 17	over 18 years
R1	Has_value Arg1:T1 Arg2:T2	
T3	Measurement 20 41	General Condition WHO
T4	Value 42 43	0
T5	Value 45 46	1
T6	Value 50 51	2
*	OR T4 T5 T6
T7	Scope 42 51	0, 1 or 2
R2	Has_scope Arg1:T3 Arg2:T7	
T8	Measurement 54 63	ASA Class
T9	Value 64 65	I
T10	Value 70 72	II
*	OR T9 T10
T11	Scope 64 72	I and II
R3	Has_scope Arg1:T8 Arg2:T11	
T12	Mood 74 86	eligible for
T13	Procedure 110 119;87 97	treatment endoscopic
T14	Procedure 101 119	surgical treatment
*	OR T14 T13
T15	Qualifier 120 140	with curative intent
T16	Scope 87 119	endoscopic or surgical treatment
R4	Has_qualifier Arg1:T16 Arg2:T15	
R5	Has_mood Arg1:T16 Arg2:T12	
R6	AND Arg1:T16 Arg2:T8	
T17	Procedure 143 165	Histological diagnosis
T18	Condition 180 210	glandular epithelial neoplasia
T19	Measurement 212 218	Vienna
T20	Value 219 230	4-1 to 4-46
R7	Has_value Arg1:T19 Arg2:T20	
T21	Qualifier 169 179	high grade
R8	Subsumes Arg1:T21 Arg2:T19	
R9	Has_qualifier Arg1:T18 Arg2:T21	
R10	AND Arg1:T18 Arg2:T17	
T22	Qualifier 242 252	multifocal
T23	Measurement 256 261	stage
T24	Value 262 263	0
R11	Has_value Arg1:T23 Arg2:T24	
T25	Measurement 265 266	T
T26	Measurement 270 271	N
T27	Measurement 274 275	M
T28	Value 275 276	0
T29	Value 271 272	0
T30	Value 266 268	is
R12	Has_value Arg1:T25 Arg2:T30	
R13	Has_value Arg1:T26 Arg2:T29	
R14	Has_value Arg1:T27 Arg2:T28	
T31	Scope 265 276	Tis, N0, M0
T32	Scope 256 263	stage 0
R15	Subsumes Arg1:T32 Arg2:T31	
R16	Has_qualifier Arg1:T18 Arg2:T22	
R17	AND Arg1:T18 Arg2:T23	
T33	Qualifier 295 317	histological confirmed
T34	Qualifier 280 290;308 317	Endoscopic confirmed
T35	Condition 331 352	intestinal metaplasia
T36	Procedure 295 307	histological
T37	Procedure 280 290	Endoscopic
R18	multi Arg1:T33 Arg2:T36	
R19	multi Arg1:T34 Arg2:T37	
*	OR T34 T33
T38	Scope 280 317	Endoscopic and histological confirmed
R20	Has_scope Arg1:T35 Arg2:T38	
T39	Qualifier 355 367	Histological
T40	Procedure 355 367	Histological
R21	multi Arg1:T39 Arg2:T40	
T41	Multiplier 391 394	two
T42	Procedure 395 406	endoscopies
R22	Has_multiplier Arg1:T42 Arg2:T41	
R23	AND Arg1:T39 Arg2:T42	
T43	Procedure 412 420	biopsies
R24	AND Arg1:T42 Arg2:T43	
T44	Multiplier 425 428	two
T45	Procedure 429 450	pathological readings
R25	Has_multiplier Arg1:T45 Arg2:T44	
R26	AND Arg1:T39 Arg2:T45	
T46	Condition 368 377	diagnosis
R27	Has_qualifier Arg1:T46 Arg2:T39	
T47	Non-representable 452 599	biopsies should be carried out according to the protocol of the SFED (four-quadrant biopsies every cm) with at least once acetic acid for staining.
T48	Non-representable 600 671	Operators describe Barrett's esophagus using he SFED planimetric model.
T49	Non-representable 672 808	The final exam will be no more than two months before the date of treatment and should have been achieved in investigator establishment,
T50	Non-representable 810 823	Minimum 1 cm,
T51	Non-representable 825 839	Maximum 12 cm.
T52	Condition 845 860	resected lesion
T53	Qualifier 876 895	well differentiated
T54	Qualifier 900 922	confined to the mucosa
T55	Qualifier 924 934	m2 maximum
T56	Procedure 939 960	histological analysis
R28	AND Arg1:T56 Arg2:T52	
R29	Has_qualifier Arg1:T52 Arg2:T53	
R30	Subsumes Arg1:T54 Arg2:T55	
R31	Has_qualifier Arg1:T52 Arg2:T54	
T57	Condition 963 972	resection
T58	Temporal 983 1003	more than two months
R32	Has_temporal Arg1:T57 Arg2:T58	
T59	Condition 1006 1015	resection
T60	Qualifier 1031 1065	macroscopically complete laterally
R33	Has_qualifier Arg1:T59 Arg2:T60	
T61	Condition 1068 1077	resection
T62	Procedure 1093 1107	histologically
T63	Qualifier 1108 1125	complete in depth
R34	Has_qualifier Arg1:T61 Arg2:T63	
R35	AND Arg1:T62 Arg2:T61	
T64	Condition 1128 1137	resection
T65	Procedure 1153 1167	histologically
T66	Qualifier 1168 1186	complete laterally
R36	Has_qualifier Arg1:T64 Arg2:T66	
T67	Non-representable 1228 1367	that is to say with a clear margin of safety (margin may be high-grade dysplasia provided that the latter has not macroscopic translation),
T68	Condition 1206 1226	microinvasive cancer
R37	AND Arg1:T66 Arg2:T68	
T69	Non-representable 1369 1551	At least one endoscopic and histologic follow-up should be conducted with dye in a period of less than two months before the date of treatment, and at the investigator establishment.
T70	Non-representable 1553 1641	Patient may take an inhibitor of proton pump equivalent to 2 times 40 mg of esomeprazole
T71	Qualifier 1683 1693	metastatic
T72	Qualifier 1662 1668	celiac
T73	Qualifier 1647 1658	mediastinal
T74	Scope 1647 1693	mediastinal or celiac, or suspected metastatic
T75	Condition 1694 1705	lymph nodes
T76	Procedure 1709 1712	EUS
T77	Negation 1644 1646	No
R38	Has_negation Arg1:T75 Arg2:T77	
R39	Has_scope Arg1:T75 Arg2:T74	
R40	AND Arg1:T76 Arg2:T75	
T78	Observation 1715 1754	Affiliation to a social security system
T79	Negation 1768 1775	Lack of
T80	Observation 1776 1792;1801 1815	participation in clinical study
T81	Qualifier 1793 1800	another
R41	Has_qualifier Arg1:T80 Arg2:T81	
R42	Has_negation Arg1:T80 Arg2:T79	
T82	Observation 1818 1841	Informed consent signed
